Young age under 60years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer
- 1 December 2011
- journal article
- conference paper
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 101 (3) , 508-512
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute, NIH (P30 CA006927)
This publication has 42 references indexed in Scilit:
- External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised studyThe Lancet Oncology, 2010
- The relationship between age at time of surgery and risk of biochemical failure after radical prostatectomyBJU International, 2010
- Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1)BMC Cancer, 2010
- Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005JNCI: Journal of the National Cancer Institute, 2009
- Timing of biochemical failure and distant metastatic disease for low‐, intermediate‐, and high‐risk prostate cancer after radiotherapyCancer, 2007
- Does age matter in the selection of treatment for men with early‐stage prostate cancer?Cancer, 2006
- Improved Biochemical Disease-Free Survival of Men Younger Than 60 Years With Prostate Cancer Treated With High Dose Conformal External Beam RadiotherapyJournal of Urology, 2003
- Biochemical Disease-Free Survival in Men Younger Than 60 Years With Prostate Cancer Treated With External Beam RadiationJournal of Urology, 2002
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988